Over the past year, the NEURO360 team worked with its partner, the St. Louis Integrated Health Network (IHN) to host nine community listening sessions across the region—hearing directly from nearly 90 patients, caregivers, health providers, patient advocates, and rural partners. This work built on early outreach supported by Dr. Joyce Balls-Berry’s research lab at Washington […]
NEURO360‑aligned research by Muriah D. Wheelock and Brian A. Gordon at WashU Medicine received a $5 million NIH grant to study how early‑life stress affects brain aging and Alzheimer’s.
NEURO360‑aligned research by Muriah D. Wheelock and Brian A. Gordon at WashU Medicine received a $5 million NIH grant to study how early‑life stress affects brain aging and Alzheimer’s.
Lan Yang has been named one of the world’s most highly cited researchers by the Institute for Scientific Information, ranking among the top 1% in her field over the past decade.
Jeff Milbrandt, MD, PhD, has been awarded the inaugural WashU Medicine Dean’s Medal for Innovation and Commercialization, recognizing his transformative discoveries in neurodegeneration and his leadership in translating breakthrough science into therapies.
NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin.
Saint Louis University’s Jenna Gorlewicz, Ph.D., has been named to the St. Louis Business Journal’s prestigious 40 Under 40 list, recognizing her leadership in engineering, research, and community impact.
A group of researchers from WashU in the McKelvey School of Engineering and the School of Medicine have created a new kind of fiber-optic device to manipulate neural activity deep in the brain. The device, called PRIME fiber, delivers multi-site, reconfigurable optical stimulation through a single, hair-thin implant.
Dr. Eric Leuthardt, neurosurgeon, scientist, entrepreneur, and co-leader of NEURO360, is advancing neurotechnology in St. Louis by translating groundbreaking research into life-changing solutions, launching companies like Neurolutions and Aurenar, and building a city-wide neurotech ecosystem.
A $3.2M NIH grant will support groundbreaking AI-driven research by WashU’s Ganesh Chand, PhD, to uncover mechanisms behind neuropsychiatric symptoms in Alzheimer’s.
